摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-amino-2,2,4,4-tetramethylcyclobutanol | 14241-17-9

中文名称
——
中文别名
——
英文名称
3-amino-2,2,4,4-tetramethylcyclobutanol
英文别名
3-amino-2,2,4,4-tetramethylcyclobutan-1-ol
3-amino-2,2,4,4-tetramethylcyclobutanol化学式
CAS
14241-17-9
化学式
C8H17NO
mdl
MFCD01734169
分子量
143.229
InChiKey
ZXDMOZCIYUTLLK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    187.9±33.0 °C(Predicted)
  • 密度:
    0.940±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    46.2
  • 氢给体数:
    2
  • 氢受体数:
    2

SDS

SDS:5f60b9c103e30de15ab9f6ce5473b29d
查看

反应信息

  • 作为反应物:
    描述:
    3-amino-2,2,4,4-tetramethylcyclobutanol磷酸 作用下, 以 乙醇 为溶剂, 反应 2.0h, 以59%的产率得到3-Amino-2,2,4,4-tetramethylcyclobutan-1-ol;phosphoric acid
    参考文献:
    名称:
    Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
    摘要:
    An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial "hit" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.
    DOI:
    10.1021/jm201059s
  • 作为产物:
    描述:
    2,2,4,4-tetramethylcyclobutane-1,3-dione 1-oxime 在 sodium tetrahydroborate 作用下, 以 四氢呋喃异丙醇 为溶剂, 反应 2.5h, 生成 3-amino-2,2,4,4-tetramethylcyclobutanol 、 3-amino-2,2,4,4-tetramethylcyclobutanol
    参考文献:
    名称:
    Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
    摘要:
    An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial "hit" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.
    DOI:
    10.1021/jm201059s
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
    申请人:Signal Pharmaceuticals, LLC
    公开号:US20150175557A1
    公开(公告)日:2015-06-25
    Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R 1 , and R 2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    本文提供具有以下结构的二氨基嘧啶化合物: 其中X、L、R1和R2如本文所定义,包含有效量二氨基嘧啶化合物的组合物,以及用于治疗或预防PKC-theta介导的疾病或通过抑制激酶(例如PKC-theta)可治疗或预防的疾病的方法。
  • 一类组蛋白乙酰化酶p300抑制剂及其用途
    申请人:海创药业股份有限公司
    公开号:CN111217802B
    公开(公告)日:2021-10-08
    本发明公开了一类组蛋白乙酰化酶p300抑制剂及其用途,属于药物化学技术领域。本发明公开了一类式(Ⅰ)所示化合物、或其立体化学异构体,或其溶剂合物、或其药学上可接受的盐。本发明公开的化合物能够有效抑制组蛋白乙酰化酶p300的活性,能够有效抑制多种肿瘤细胞的增殖活性。同时,本发明化合物与CDK4/6抑制剂联用,在抑制肿瘤细胞的增殖中发挥了协同作用。因此,本发明的化合物在制备组蛋白乙酰化酶抑制剂,制备预防和/或治疗癌症、代谢类疾病、神经类疾病或炎症的药物以及联合用药物中具有非常好的应用前景。
  • Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
    申请人:Signal Pharmaceuticals, LLC
    公开号:US09156798B2
    公开(公告)日:2015-10-13
    Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R1, and R2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.
    本文提供了具有以下结构的二氨基嘧啶化合物:其中X,L,R1和R2如本文所定义,包含有效量的二氨基嘧啶化合物的组合物,以及用于治疗或预防PKC-theta介导的疾病或可通过抑制激酶(例如PKC-theta)治疗或预防的疾病的方法。
  • Branched amides of L-aspartyl-D-amino acid dipeptides and compositions thereof
    申请人:PFIZER INC.
    公开号:EP0034876A2
    公开(公告)日:1981-09-02
    Amides of L-aspartyl-D-amino acid dipeptides of the formula and physiologically acceptable cationic and acid addition salts thereof wherein Ra is methyl, ethyl, n-propyl or isopropyl and R is a branched aliphatic, alicyclic or heterocyclic member which is branched at the alpha carbon atom (the carbon atom bearing the amide nitrogen atom) and also branched again at one or both of the beta carbon atoms, are potent sweeteners which are free from undesirable flavour qualities and of high stability in conventional food processing. Sweetening compositions and sweetened edible compositions of such amides are also claimed
    式中 L-天冬酰-D-氨基酸二肽的酰胺类 及其生理上可接受的阳离子盐和酸加成盐,其中 Ra 为甲基、乙基、正丙基或异丙基,R 为支链脂环族、脂环族或杂环族成员,该成员在 α 碳原子(含酰胺氮原子的碳原子)上有支链,在一个或两个β碳原子上也有支链。这种酰胺的甜味组合物和甜味可食用组合物也已申请专利。
  • PROCESS FOR THE PREPARATION OF SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS
    申请人:Signal Pharmaceuticals, LLC
    公开号:EP3736268A1
    公开(公告)日:2020-11-11
    The invention provides a method for preparing a compound of formula (I): comprising contacting a compound of formula (Ia) or a compound of formula (Ic) with R1-L-NH2, in an organic solvent, in the presence of a base, under conditions as defined herein. Also provided are reaction intermediates involved in said method as defined herein.
    本发明提供了一种制备式 (I) 化合物的方法: 包括将式(Ia)化合物 或式(Ic)化合物 与 R1-L-NH2,在有机溶剂中,在碱存在下,在本文定义的条件下进行。还提供了参与所述方法的反应中间体,如本文所定义。
查看更多